Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 Following Administration of SEL-110) in Pediatric Subjects With Mut Subtype Isolated Methylmalonic Acidemia (MMA)

Next Previous
X
Search
Trial Profile

Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 Following Administration of SEL-110) in Pediatric Subjects With Mut Subtype Isolated Methylmalonic Acidemia (MMA)

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autoimmune therapy Cartesian Therapeutics (Primary) ; Sel 302 (Primary)
  • Indications Methylmalonic acidaemia
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms reiMMAgine
  • Sponsors Selecta Biosciences

    • Most Recent Events

    • 04 May 2023 Status changed to suspended, according to a Selecta Biosciences media release.
    • 04 May 2023 According to a Selecta Biosciences media release, company will pause further development of its wholly-owned gene therapy programs, including the ongoing Phase 1/2 clinical trial of SEL-302. The Company is currently assessing ways to support further development of these programs through potential partnerships.
    • 02 Mar 2023 Status changed from planning to recruiting, according to a Selecta Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top